Shares of Glenmark Pharmaceuticals rose by nearly 2% following Ichnos Glenmark Innovation’s (IGI) announcement of encouraging Phase 1 trial results for its trispecific antibody, ISB 2001, targeting relapsed/refractory multiple myeloma (r/rMM). The findings will be presented at the upcoming 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.
Key Highlights
- ISB 2001 Safety and Efficacy: The Phase 1 study of ISB 2001 demonstrated a favorable safety profile and an impressive overall response rate (ORR) of 75% in r/rMM patients, indicating its potential as a novel treatment option.
- Additional Study on ISB 1442: IGI is set to present additional safety and tolerability data from the Phase 1/2 study of ISB 1442, another investigational therapy for r/rMM.
Presentation Schedule
- ISB 2001 Oral Presentation: Hang Quach, M.B.B.S., will present the findings on December 9, 2024, at the San Diego Convention Center, Hall B.
- ISB 1442 Poster Presentation: Binod Dhakal, M.D., will present data on December 8, 2024, at the San Diego Convention Center, Halls G-H.
As of 9:37 am, Glenmark Pharmaceuticals’ shares were trading 1.46% higher at ₹1,750.35 on the NSE, reflecting investor optimism around these promising developments in cancer therapy.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice.
